Clinical trial
NGX-4010 for the Treatment of Postherpetic Neuralgia
NCT00061776 · NeurogesX, Industry · Completed
Key facts
| NCT number | NCT00061776 |
|---|---|
| Title | NGX-4010 for the Treatment of Postherpetic Neuralgia |
| Official title | A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia |
| Lead sponsor | NeurogesX, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles |
| Intervention type | Drug |
| Interventions | Capsaicin Dermal Patch |
| Enrollment | 300 |
| First posted | Jun 4, 2003 |
| Last update posted | Mar 6, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: